Compare CACC & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CACC | MMED |
|---|---|---|
| Founded | 1972 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.5B |
| IPO Year | 1996 | 2025 |
| Metric | CACC | MMED |
|---|---|---|
| Price | $570.54 | $19.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $505.00 | $22.56 |
| AVG Volume (30 Days) | 110.4K | ★ 1.1M |
| Earning Date | 05-05-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.00 | N/A |
| EPS | ★ 25.04 | N/A |
| Revenue | $2,317,200,000.00 | ★ $3,102,000,000.00 |
| Revenue This Year | $91.73 | $15.99 |
| Revenue Next Year | $3.58 | $10.00 |
| P/E Ratio | $22.89 | ★ N/A |
| Revenue Growth | 7.16 | ★ 14.25 |
| 52 Week Low | $401.90 | $10.65 |
| 52 Week High | $668.86 | $20.88 |
| Indicator | CACC | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 63.46 |
| Support Level | $535.20 | $10.68 |
| Resistance Level | $621.52 | N/A |
| Average True Range (ATR) | 18.61 | 0.84 |
| MACD | 0.31 | -0.02 |
| Stochastic Oscillator | 34.54 | 63.66 |
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.